Three ownership structures, three risk profiles

Programmes with several named partners can reroute a prescription when one facility has a problem. Programmes with one owned facility cannot.

Ownership also determines who is accountable: when the platform and the pharmacy are the same company, the state board licensing the pharmacy is the only external check.

The question is rarely asked and simple: do you own the pharmacy that fills my prescription, and if not, how many do you work with?

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.

What the spread actually represents

All-in cost runs $215 to $597 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.

5 of 16 charge a mandatory recurring fee and 12 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.

Where our numbers could be wrong

A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.

All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.

Why the cheapest entries are the least reliable

Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.

Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.

Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.

How to sanity-check any figure you find elsewhere

Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.

Tirzepatide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Tirzepatide costs X' is not a sentence that can be true without naming the product and the channel.

What stopping does, and why it belongs in a cost calculation

The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.

Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.

Why the same molecule sells across a fifteenfold range

The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.

That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.

What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.

The pharmacology behind the fees

Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.

A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.